IMR Press / EJGO / Volume 23 / Issue 5 / pii/2002202

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Neoadjuvant chemotherapy in ovarian cancer

Show Less
1 Gaziantep University, Medical Faculty, Departments of Medical Oncology, Gaziantep (Turkey)
2 Gaziantep University, Medical Faculty, Departments of Obstetrics and Gynecology, Gaziantep (Turkey)
Eur. J. Gynaecol. Oncol. 2002, 23(5), 437–441;
Published: 10 October 2002

Patients with advanced ovarian cancer have a chance of less than 50% after radical debulking surgery. In spite of the currently more effective combmat10n chemotherapy agents that have become available as adjuvant therapy in the last decade, the prognosis of patients with residual tumor mass larger than 1 cm in diameter following surgery is still poor. Neoadjuvant or primary che­motherapy has been suggested as an alternative approach to primary laparotomy of the bulky ovarian cancer. The advantages and available data on neoadJuvant chemotherapy are discussed in this review.

Neodjuvant chemotherapy
Ovarian cancer
Back to top